IsoPlexis Corporation
The momentum for this stock is not very good. IsoPlexis Corporation is not a good value stock. IsoPlexis Corporation is not a good growth stock. Tradey thinks it is not wise to invest in IsoPlexis Corporation.
Log in to see more information.
News
IsoPlexis Full Year 2022 Earnings: Misses Expectations
Simply Wall St Revenue: US$16.8m (down 2.9% from FY 2021). Net loss: US$106.0m (loss widened by 15% from FY 2021). US$2.70 loss per share. All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue missed analyst estimates by 14%. Earnings per share (EPS) also missed analyst estimates by 21%.\n more…
IsoPlexis (NASDAQ:ISO) versus Quanterix (NASDAQ:QTRX) Financial Contrast
Zolmax Quanterix (NASDAQ:QTRX Get Rating) and IsoPlexis (NASDAQ:ISO Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, risk, valuation, dividends ...\n more…